PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.55%
Revenue growth above 1.5x CFLT's 4.12%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
8.14%
Gross profit growth above 1.5x CFLT's 3.03%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
60.83%
EBIT growth above 1.5x CFLT's 4.68%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
61.13%
Operating income growth above 1.5x CFLT's 4.68%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
70.37%
Positive net income growth while CFLT is negative. John Neff might see a big relative performance advantage.
-110.47%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-110.47%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.84%
Share count expansion well above CFLT's 1.62%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.84%
Diluted share count expanding well above CFLT's 1.62%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
49.55%
OCF growth under 50% of CFLT's 167.71%. Michael Burry might suspect questionable revenue recognition or rising costs.
55.30%
FCF growth under 50% of CFLT's 161.02%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
88.33%
10Y revenue/share CAGR under 50% of CFLT's 244.52%. Michael Burry would suspect a lasting competitive disadvantage.
88.33%
5Y revenue/share CAGR under 50% of CFLT's 244.52%. Michael Burry would suspect a significant competitive gap or product weakness.
35.59%
3Y revenue/share CAGR at 50-75% of CFLT's 65.14%. Martin Whitman would question if the firm lags behind competitor innovations.
166.35%
10Y OCF/share CAGR in line with CFLT's 155.49%. Walter Schloss would see both as similarly efficient over the decade.
166.35%
5Y OCF/share CAGR is similar to CFLT's 155.49%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
154.90%
3Y OCF/share CAGR similar to CFLT's 144.14%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
87.21%
Positive 10Y CAGR while CFLT is negative. John Neff might see a substantial advantage in bottom-line trajectory.
87.21%
Positive 5Y CAGR while CFLT is negative. John Neff might view this as a strong mid-term relative advantage.
97.82%
3Y net income/share CAGR above 1.5x CFLT's 43.18%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
182.87%
Equity/share CAGR of 182.87% while CFLT is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
182.87%
Equity/share CAGR of 182.87% while CFLT is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-46.77%
Negative 3Y equity/share growth while CFLT is at 8.89%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.94%
AR growth well above CFLT's 20.06%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.16%
Inventory is declining while CFLT stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.61%
Asset growth above 1.5x CFLT's 4.40%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.12%
BV/share growth above 1.5x CFLT's 2.08%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.60%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.82%
Our R&D shrinks while CFLT invests at 3.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.35%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.